Edition:
United Kingdom

People: Ligand Pharmaceuticals Inc (LGND.OQ)

LGND.OQ on NASDAQ Stock Exchange Global Market

147.93USD
12 Dec 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$147.93
Open
$147.97
Day's High
$151.86
Day's Low
$146.68
Volume
127,057
Avg. Vol
207,728
52-wk High
$277.48
52-wk Low
$133.50

Kozarich, John 

Dr. John W. Kozarich is Non-Executive Independent Chairman of the Board of the Company. Dr. Kozarich currently serves as Distinguished Scientist and Executive Advisor of ActivX Biosciences, Inc., and previously served as ActivX’s Chairman and President from 2004 through March 2017. From 1992 to 2001, he was vice president at Merck Research Laboratories and previously held professorships at the University of Maryland and Yale University School of Medicine. Dr. Kozarich is also an adjunct professor of Chemical Physiology at the Scripps Research Institute and serves on boards, including ActivX Biosciences Inc., Retrophin, Inc. and Intec Pharma Ltd. Previously, Dr. Kozarich served as a director of Corium Intl and Novelium Therapeutics. He is also a recent recipient of the Distinguished Scientist Award from the San Diego Section of the American Chemical Society. Dr. Kozarich earned his B.S. in chemistry, summa cum laude, from Boston College, his Ph.D. in biological chemistry from the Massachusetts Institute of Technology, and was an NIH Postdoctoral Fellow at Harvard. In selecting Dr. Kozarich to serve as a director, the board considered, among other things, his valuable pharmaceutical and international experience, including his service at Merck Research Laboratories, which is part of one of the world’s largest pharmaceutical companies, and his service with ActivX Biosciences, Inc., Novelion Therapeutics Inc. and Corium Intl. Ligand also benefits from Dr. Kozarich’s financial and accounting experience in the pharmaceutical and biotechnology industries.

Basic Compensation

Total Annual Compensation, USD --
Restricted Stock Award, USD 75,591
Long-Term Incentive Plans, USD --
All Other, USD 215,487
Fiscal Year Total, USD 291,078

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

John Kozarich

291,078

Matthew Foehr

3,458,500

John Higgins

5,513,210

Matthew Korenberg

2,185,720

Charles Berkman

1,498,820

Jason Aryeh

277,156
As Of  31 Dec 2017